Skip to main content
Fig. 1 | The Journal of Physiological Sciences

Fig. 1

From: Vidarabine, an anti-herpes agent, prevents occlusal-disharmony-induced cardiac dysfunction in mice

Fig. 1

Schematic illustrations of experimental procedure and bite-opening treatment, and comparison of body weight, cardiac muscle weight and lung weight among the groups. a Male 16-week-old C57BL/6 mice were divided into four groups: a normal control group (CTRL), a bite-opening (BO)-treated group, a vidarabine-treated group (V), and a BO plus vidarabine-treated (BO + V) group. Long-term infusion of vidarabine was performed for 14 days at a dose of 15 mg/kg/day with the osmotic mini-pumps, and the indicated measurements were made. b Schematic representation of a bite-opening (BO) in the form of a 0.7 mm increase in the vertical height of occlusion, obtained by cementing a composite resin onto the mandibular incisors to cause occlusal disharmony in mice. c Body weight was measured daily for all animals throughout the 2-week experimental period. ****P < 0.0001 (Control (n = 5) vs. BO (n = 5), ####P < 0.0001 (Control vs. BO + V (n = 5), ‡‡‡‡P < 0.0001 (BO vs. V (n = 5)), ※※※※P < 0.0001 (V vs. BO + V) by two-way repeated-measures ANOVA followed by the Bonferroni post hoc test. d, e No significant difference in heart (d) or lung (e) size in terms of weight per tibial length ratio (mg/mm) at 2 weeks after BO treatment (Control (n = 5), BO (n = 5), vidarabine (n = 5) and BO + vidarabine (n = 5) groups; P = NS, not significantly different, vs. Control by one-way ANOVA) followed by the Tukey–Kramer post hoc test. Data are presented as mean ± SD

Back to article page